Tag: Glivec
-
Novartis' Glivec extends European GIST licence
Novartis' Glivec extends European GIST licence Novartis' cancer therapy Glivec (imatinib) can now be used in Europe to treat specific patients with gastrointestinal stromal tumours (GIST) up to 3 years right after surgery. The European Commission (EC) has approved an update to the labelling for the … Read much more on PMLiVE Positive Vote for…